Caco-2 permeability Other: Has the project generated metabolism data (rodent / Yes No Not in vitro non-rodent / human)? assessed Is there consistency in the metabolism rates across Yes No Not in vitro non-clinical species and man assessed Comments on metabolism if needed: in vitro Has the project generated exposure or PK data on an Yes No Not in vivo active compound in a rodent species? assessed What PK parameters have you measured? Animal model Human Plasma Clearance Plasma Clearance %bioavailability (F) %bioavailability (F) i.v. plasma half life i.v. plasma half life Plasma protein binding Plasma protein binding Other: Other: Has the project access to relevant disease models or other Yes No Not pharmacodynamics models? assessed Has the project generated efficacy data? Yes No Not in vivo assessed Has target engagement been assessed? Yes No Not in vivo assessed If yes, briefly describe how: Is there information known about the series with respect to Yes No Not hERG and/or CYP450 inhibition/induction? assessed Comment on preclinical package: Preclinical Package NB for biologicals only – Do you have biological assays in place for lead Yes No optimisation? Not applicable No assays model(s) In vivo Biochemical assay Other: Cellular assay Other: What kind of pharmacological data has the project generated? in vitro Describe briefly Has the project generated exposure or PK data on an Yes No Not in vivo active compound in a rodent species? assessed What PK parameters have you measured? Animal model Human Clearance Clearance %bioavailability (F) %bioavailability (F) Serum half-life Serum half-life
Caco-2 permeability Other: Has the project generated in vitro metabolism data (rodent / non-rodent / human)? Yes No Not assessed Is there consistency in the in vitro metabolism rates across non-clinical species and man Yes No Not assessed Comments on in vitro metabolism if needed: Has the project generated in vivo exposure or PK data on an active compound in a rodent species? Yes No Not assessed What PK parameters have you measured? Animal model Plasma Clearance %bioavailability (F) i.v. plasma half life Plasma protein binding Other: Human Plasma Clearance %bioavailability (F) i.v. plasma half life Plasma protein binding Other: Has the project access to relevant disease models or other pharmacodynamics models? Yes No Not assessed Has the project generated in vivo efficacy data? Yes No Not assessed Has in vivo target engagement been assessed? Yes No Not assessed If yes, briefly describe how: Is there information known about the series with respect to hERG and/or CYP450 inhibition/induction? Yes No Not assessed Comment on preclinical package: Preclinical Package – NB for biologicals only Do you have biological assays in place for lead optimisation? Yes No Not applicable No assays Biochemical assay Cellular assay In vivo model(s) Other: Other: What kind of in vitro pharmacological data has the project generated? Describe briefly Has the project generated in vivo exposure or PK data on an active compound in a rodent species? Yes No Not assessed What PK parameters have you measured? Animal model Clearance %bioavailability (F) Serum half-life Human Clearance %bioavailability (F) Serum half-life